BioCentury
ARTICLE | Clinical News

TD-9855: Development discontinued

December 16, 2013 8:00 AM UTC

Theravance disclosed in a November SEC filing that the company will discontinue development of TD-9855 to treat ADHD after data from a double-blind, U.S. Phase II trial showed the compound missed the primary endpoint of symptom reduction as measured by AISRS total score vs. placebo. TD-9855 was generally well tolerated with no serious adverse events reported. The most common adverse events reported were headache, dizziness, reduced appetite, fatigue and dry mouth. The trial enrolled about 285 adult male ADHD patients to receive placebo or once-daily 5 or 20 mg oral TD-9855 for 6 weeks. Data from a Phase II trial evaluating TD-9855 to treat fibromyalgia are expected in 1H14. ...